ATC 1906

Drug Profile

ATC 1906

Alternative Names: ATC-1906

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator Altos Therapeutics
  • Class Gastrokinetics
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastroparesis

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Gastroparesis in USA (PO) before July 2016
  • 01 Jul 2016 Altos Therapeutics enters into a definitive agreement with Takeda to advance development of ATC 1906 for Gastroparesis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top